NAP (Davunetide) vs PACAP-38 — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
NAP (NAPVSIPQ) is an eight-amino-acid neuroprotective peptide derived from Activity-Dependent Neuroprotective Protein (ADNP) - a zinc-finger protein essential for brain formation that is one of the most abundant transcription factors in the brain. First identified by Illana Gozes...
Calculate NAP (Davunetide) dose →Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP-38) is a 38-amino-acid member of the VIP/secretin/glucagon superfamily, first isolated from ovine hypothalamus in 1989 by Miyata and colleagues based on its ability to stimulate adenylate cyclase in pituitary cells. PACAP-...
Calculate PACAP-38 dose →| Parameter | NAP (Davunetide) | PACAP-38 |
|---|---|---|
| Category | Neuropeptides & Cognition | Neuropeptides & Cognition |
| Research | Phase II Completed (PSP, Schizophrenia) | Extensively Studied (Preclinical) |
| Half-Life | 1-3 h (estimated) | 2-5 min (plasma); longer in CNS |
| Typical Dose | 30-300 mcg intranasal | 300-600 mcg intranasal; 100-300 mcg SC |
| Frequency | Twice daily | As needed or daily for neuroprotection protocols |
| Route | Intranasal (preferred for CNS delivery) | Intranasal, Subcutaneous, IV |
| FDA Status | Not Approved | Not Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.